Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Fredun Pharmaceuticals has informed that the Board of Directors of the Company at its meeting held Wednesday, May 24, 2023 at 04.00 pm has considered, adopted and approved following items of business: The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. The company has enclosed: A copy of the said Financial Results along with the Auditor's Report thereon & Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10 each for the Financial Year 2022-23; subject to the approval of the Shareholders at the ensuing 36th Annual General Meeting of the Company. In furtherance to the intimation filed by the Company dated March 31, 2023; the trading window for trading in securities of the Company by insiders closed on April 01, 2023 till the end of 48 hours after the declaration of outcome of Board Meeting. The Board Meeting commenced at 04.00 pm and concluded at 00:15 am.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1709.40 |
Dr. Reddys Lab | 1109.75 |
Cipla | 1415.55 |
Lupin | 1971.10 |
Zydus Lifesciences | 866.65 |
View more.. |